In this webinar hosted by GEN, you will learn how the Finnish Institute of Molecular Medicine (FIMM) and AstraZeneca leveraged the unique capabilities of IntelliCyt’s iQue Screener platform to generate high-content data at high-speeds on heterogeneous cell populations using miniaturized cellular assays, or in multiplexed, ultra-miniaturized, bead-based assay formats. The iQue Screener enables more physiologically relevant assays to be performed faster, while conserving precious samples, saving costs and overcoming the limitations of traditional approaches.
The webinar will highlight:
- How FIMM develops precision medicine strategies for blood cancer patients through multiparametric drug sensitivity and resistance tests used to identify drugs and drug combinations that can effectively target tumor cells and monitor drug effects on immune cell response.
- How AstraZeneca ran a 500 thousand compound cell viability screen and a target specific bead-based assay involving three of the major risk genes/factors associated with Amyotrophic Lateral Sclerosis (ALS) to identify novel inhibitors of target-induced toxicity.
- Catherine Bardelle, Ph.D., Senior Scientist, AstraZeneca
- Caroline Heckman, Ph.D., Principal Investigator, FIMM